In addition, sildenafil significantly improved Vo2max.98 These findings by themselves are very valuable but are also important in the context of safety: Sildenafil can be safely used in patients with heart failure and pulmonary hypertension, in contrast to other pulmonary vasodilators. In contrast, the endothelin antagonist bosentan has been associated with fluid retention and failure to improve symptoms of heart failure,101 and the prostacyclin analogue epoprostenol has been associated with increased mortality, especially in patients with coronary artery disease.102 Researchers in a second trial also evaluated the chronic effect of sildenafil on hemodynamics, as well as exercise dynamics. Guazzi and coworkers103 randomly assigned 46 male patients with NYHA functional class II or III heart failure (the presence of pulmonary hypertension was not necessary for inclusion) to receive sildenafil or placebo. At 3 and 6 months, the sildenafil-treated patients demonstrated a reduction in systolic pulmonary artery pressure, a reduction in ergoreflex effect on ventilation, an improvement in Vco2 production slope and Vo2max, and improvements in breathlessness score and flow-mediated vasodilation. The improvement in exercise efficiency was attributed to improved cardiopulmonary hemodynamics and improved sensitivity of the ergoventilatory reflex (a reflex that couples mechanoreceptors or chemoreceptors, or both, in exercising skeletal muscle to the control of ventilation), which, in turn, was possibly a result of improved skeletal muscle perfusion.

The increase in cardiac output with sildenafil treatment has been attributed largely to an improvement in right ventricular function (which results from a decrease in pulmonary artery pressures) and to a decrease in systemic vascular resistance.

Several observations support the concept that sildenafil has positive inotropic properties.

• Sildenafil citrate is a phosphodiesterase type 5 inhibitor.
• Sublingual tablets offer an alternative for those with swallowing difficulties.
• The medication is designed to be fast-acting for spontaneous activity.
• Avoid use if you have a history of stroke or heart attack.
• Always check expiration dates before use.
• Female patients should not use sildenafil medication.
• Report any persistent pain or abnormal erections.
• Combining sildenafil with recreational drugs can be dangerous.
• The sublingual form minimizes gastrointestinal side effects.
• Use the lowest effective dose to minimize adverse effects.
• Consult your doctor about safe usage and potential interactions.

In patients given inhaled nitric oxide with comparable reductions in the pulmonary vascular resistance, an increase in cardiac output was not noted in comparison to sildenafil.104 Moreover, Nagendran and associates105 confirmed a lack of phosphodiesterase type 5 in normal human right ventricular myocardium but were able to demonstrate its presence in hypertrophied right ventricular myocardium. In addition, they were able to show a positive inotropic effect with phosphodiesterase type 5 inhibition in this tissue. The mechanism of positive inotropy remains to be elucidated. Moreover, novel exciting data suggest that cGMP-dependent protein kinases are involved in the reversal of myocardial hypertrophy and subsequent improvement in ventricular function; thus, phosphodiesterase type 5 inhibitors may have a role in the treatment of ventricular hypertrophy and reverse remodeling. In an animal model of ventricular hypertrophy induced by pressure overload, sildenafil administration prevented the development of ventricular hypertrophy and, in animals with established hypertrophy, reversed the hypertrophy.

• Sildenafil citrate sublingual tablets can improve quality of life.
• Not recommended for use in individuals with low blood pressure.
• Use with caution in patients with liver or kidney impairment.
• The tablet should be placed under the tongue, not chewed.
• Immediate medical attention is required if an erection lasts more than 4 hours.
• Alcohol consumption may increase side effects.
• Patients should avoid driving until effects are known.
• Always follow the dosing instructions provided by your doctor.
• Do not take other ED medications concurrently.
• The medication is not a cure but manages symptoms.
• Report any unusual side effects to your healthcare provider.

The postulated mechanisms are improved calcium handling, sildenafil-induced increase in cGMP concentration, and thus increase in cGMP-dependent protein kinase activity, which in turn appears to lead to a decrease in downstream hypertrophy signaling. At the same time, animals treated with sildenafil showed an improvement in ventricular systolic function.96,106 These findings are very encouraging and suggest that sil-denafil may successfully and safely decrease pulmonary artery pressures in patients with systolic heart failure and improve symptoms and exercise capacity even in patients with heart failure but without significant pulmonary hypertension.103 Larger prospective clinical trials are needed to confirm these findings and to evaluate the benefit of this agent on morbidity and mortality outcomes in patients with systolic heart failure. Moreover, the evidence that sildenafil may reverse hypertrophy suggests that it may have a role in the treatment of diastolic heart failure, as reviewed in detail in Chapter 48. Aspargo plans to file a new drug application with the FDA to support regulatory approval of ASP-001 for erectile dysfunction in the United States. Findings from a recent phase 1 trial show that ASP-001, an investigational sildenafil oral spray for patients with erectile dysfunction, achieved therapeutic levels at a significantly faster rate compared with traditional sildenafil citrate tablets (Viagra), announced Aspargo Labs, the developer of the formulation, in a news release.1 “The rapid and enhanced absorption profile demonstrated by ASP-001 in this phase 1 study highlight its potential to address key unmet needs in the treatment of erectile dysfunction,” said Steven Kaplan, MD, Chief Medical Officer at Aspargo Labs, director of the Men’s Wellness Program at the Mount Sinai Health System, and a professor at the Icahn School of Medicine at Mount Sinai.1 “Many patients struggle with the inconvenience and lack of spontaneity associated with planning ahead to take a tablet and the requirement to fast or time their dosing. An oral spray formulation that achieves therapeutic levels quickly could represent a significant advancement in patient-centric therapy. If approved, ASP-001 would be a welcome addition to the treatment landscape, offering patients and their partners a novel and practical option to enhance their sexual health and overall quality of life.” Overall, data from the phase 1 study showed that ASP-001 achieved initial absorption within 5 minutes of administration.

At this time point, the average amount of medication in the bloodstream was 0.615 ng/mL with ASP-001, vs 0 ng/mL with sildenafil tablets.

• The sublingual route offers an alternative for patients with GI issues.
• They are suitable for those who need rapid erectile function support.
• Use only as directed; overdose can cause serious health risks.
• Avoid taking with high-fat meals to improve absorption.
• Be aware of potential side effects like headache or indigestion.
• Do not use if you are taking other medications for pulmonary hypertension without consulting.
• Take care when operating machinery until effects are known.
• This medication does not protect against sexually transmitted infections.
• Regularly review treatment efficacy with your healthcare provider.
• Be aware of contraindications with nitrate drugs.
• Proper hydration may assist in medication effectiveness.

The average level of medication in the bloodstream via mean plasma concentrations remained higher for those who received ASP-001 vs those who received sildenafil tablets for the first 30 minutes following administration. In total, the open-label, single center, 2-way crossover study included 53 healthy, fasted male volunteers.

Further information

The average level of medication in the bloodstream via mean plasma concentrations remained higher for those who received ASP-001 vs those who received sildenafil tablets for the first 30 minutes following administration. In total, the open-label, single center, 2-way crossover study included 53 healthy, fasted male volunteers. Participants were randomly assigned to receive either 4 mL of ASP-001 or to 100 mg sildenafil tablets. All those included in the trial participated in at least a 10-hour fasting period and underwent a total of 24 plasma blood samples over 24 hours. In addition to the current phase 1 study, ASP-001 is also being assessed in a companion food-effect trial to compare the amount of active drug in participants’ plasma following an administration of the medication under both fed and fasted conditions.2 In total, the study plans to enroll 38 participants.

CAUTION & WARNING:

Sildenafil oral spray is currently approved in Spain, Germany, the Netherlands, Ireland, Mexico and the United Kingdom. Aspargo now plans to file a sildenafil citrate 150 mg red pill new drug application with the FDA to support regulatory approval of ASP-001 in the United States. Aspargo is also working on regulatory submissions to support approval of ASP-001 in Japan as well as several countries in the Middle East and South America. “Our innovative oral spray technology has been carefully developed to provide a novel approach for administering medication, simplifying the process of drug consumption,” said Michael Demurjian, CEO of Aspargo Labs, in the news release.1 “The study data provides evidence for the safety and pharmacokinetic profile of our oral spray technology. Our research has demonstrated that ASP-001 exhibits rapid absorption, surpassing the absorption rate of Viagra tablets in the initial minutes after administration. Participants were randomly assigned to receive either 4 mL of ASP-001 or to 100 mg sildenafil tablets. All those included in the trial participated in at least a 10-hour fasting period and underwent a total of 24 plasma blood samples over 24 hours. In addition to the current phase 1 study, ASP-001 is also being assessed in a companion food-effect trial to compare the amount of active drug in participants’ plasma following an administration of the medication under both fed and fasted conditions.2 In total, the study plans to enroll 38 participants. Sildenafil oral spray is currently approved in Spain, Germany, the Netherlands, Ireland, Mexico and the United Kingdom. Aspargo now plans to file a sildenafil citrate 150 mg red pill new drug application with the FDA to support regulatory approval of ASP-001 in the United States. Aspargo is also working on regulatory submissions to support approval of ASP-001 in Japan as well as several countries in the Middle East and South America.

“Our innovative oral spray technology has been carefully developed to provide a novel approach for administering medication, simplifying the process of drug consumption,” said Michael Demurjian, CEO of Aspargo Labs, in the news release.1 “The study data provides evidence for the safety and pharmacokinetic profile of our oral spray technology.

More about sildenafil

Our research has demonstrated that ASP-001 exhibits rapid absorption, surpassing the absorption rate of Viagra tablets in the initial minutes after administration.

Chemical synthesis

In addition, sildenafil significantly improved Vo2max.98 These findings by themselves are very valuable but are also important in the context of safety: Sildenafil can be safely used in patients with heart failure and pulmonary hypertension, in contrast to other pulmonary vasodilators. In contrast, the endothelin antagonist bosentan has been associated with fluid retention and failure to improve symptoms of heart failure,101 and the prostacyclin analogue epoprostenol has been associated with increased mortality, especially in patients with coronary artery disease.102 Researchers in a second trial also evaluated the chronic effect of sildenafil on hemodynamics, as well as exercise dynamics. Guazzi and coworkers103 randomly assigned 46 male patients with NYHA functional class II or III heart failure (the presence of pulmonary hypertension was not necessary for inclusion) to receive sildenafil or placebo. At 3 and 6 months, the sildenafil-treated patients demonstrated a reduction in systolic pulmonary artery pressure, a reduction in ergoreflex effect on ventilation, an improvement in Vco2 production slope and Vo2max, and improvements in breathlessness score and flow-mediated vasodilation. The improvement in exercise efficiency was attributed to improved cardiopulmonary hemodynamics and improved sensitivity of the ergoventilatory reflex (a reflex that couples mechanoreceptors or chemoreceptors, or both, in exercising skeletal muscle to the control of ventilation), which, in turn, was possibly a result of improved skeletal muscle perfusion.

1. State-of-the-Art Manufacturing Facilities

The increase in cardiac output with sildenafil treatment has been attributed largely to an improvement in right ventricular function (which results from a decrease in pulmonary artery pressures) and to a decrease in systemic vascular resistance. Several observations support the concept that sildenafil has positive inotropic properties. In patients given inhaled nitric oxide with comparable reductions in the pulmonary vascular resistance, an increase in cardiac output was not noted in comparison to sildenafil.104 Moreover, Nagendran and associates105 confirmed a lack of phosphodiesterase type 5 in normal human right ventricular myocardium but were able to demonstrate its presence in hypertrophied right ventricular myocardium. In addition, they were able to show a positive inotropic effect with phosphodiesterase type 5 inhibition in this tissue. The mechanism of positive inotropy remains to be elucidated. We look forward to collaborating with the FDA to file an NDA for ASP-001 for the treatment of ED under the 505(b)2 regulatory pathway and are enthusiastic about the opportunity to make this drug available to patients in the US.” Aspargo Labs announces data on first oral spray for erectile dysfunction, ASP-001, showing two times faster absorption compared to Viagra tablets. Aspargo announces completion of dosing of all subjects in sildenafil oral suspension bioavailability study and initiation of dosing in companion food-effect study. Background : The aim of the present study was to show the efficacy and safety of sublingual sildenafil and to determine whether lower doses cause the same effect with a faster onset of action in this mode of application. Methods : Fourty consecutive patients with erectile dysfunction for more than three months were included in the study.

What Is Silenafil and How Does It Work?

Moreover, novel exciting data suggest that cGMP-dependent protein kinases are involved in the reversal of myocardial hypertrophy and subsequent improvement in ventricular function; thus, phosphodiesterase type 5 inhibitors may have a role in the treatment of ventricular hypertrophy and reverse remodeling. In an animal model of ventricular hypertrophy induced by pressure overload, sildenafil administration prevented the development of ventricular hypertrophy and, in animals with established hypertrophy, reversed the hypertrophy. The postulated mechanisms are improved calcium handling, sildenafil-induced increase in cGMP concentration, and thus increase in cGMP-dependent protein kinase activity, which in turn appears to lead to a decrease in downstream hypertrophy signaling. At the same time, animals treated with sildenafil showed an improvement in ventricular systolic function.96,106 These findings are very encouraging and suggest that sil-denafil may successfully and safely decrease pulmonary artery pressures in patients with systolic heart failure and improve symptoms and exercise capacity even in patients with heart failure but without significant pulmonary hypertension.103 Larger prospective clinical trials are needed to confirm these findings and to evaluate the benefit of this agent on morbidity and mortality outcomes in patients with systolic heart failure. Moreover, the evidence that sildenafil may reverse hypertrophy suggests that it may have a role in the treatment of diastolic heart failure, as reviewed in detail in Chapter 48.

5. Target Countries and Export Markets

Aspargo plans to file a new drug application with the FDA to support regulatory approval of ASP-001 for erectile dysfunction in the United States. Findings from a recent phase 1 trial show that ASP-001, an investigational sildenafil oral spray for patients with erectile dysfunction, achieved therapeutic levels at a significantly faster rate compared with traditional sildenafil citrate tablets (Viagra), announced Aspargo Labs, the developer of the formulation, in a news release.1 “The rapid and enhanced absorption profile demonstrated by ASP-001 in this phase 1 study highlight its potential to address key unmet needs in the treatment of erectile dysfunction,” said Steven Kaplan, MD, Chief Medical Officer at Aspargo Labs, director of the Men’s Wellness Program at the Mount Sinai Health System, and a professor at the Icahn School of Medicine at Mount Sinai.1 “Many patients struggle with the inconvenience and lack of spontaneity associated with planning ahead to take a tablet and the requirement to fast or time their dosing. An oral spray formulation that achieves therapeutic levels quickly could represent a significant advancement in patient-centric therapy. If approved, ASP-001 would be a welcome addition to the treatment landscape, offering patients and their partners a novel and practical option to enhance their sexual health and overall quality of life.” Overall, data from the phase 1 study showed that ASP-001 achieved initial absorption within 5 minutes of administration. At this time point, the average amount of medication in the bloodstream was 0.615 ng/mL with ASP-001, vs 0 ng/mL with sildenafil tablets. The mean age was 55 years (range, 25-65). Serum glucose and testosterone levels, lipid profile and erectile function scores were obtained in all patients.

• Sildenafil citrate sublingual tablets are part of ED treatment options.
• They should be stored securely to prevent unauthorized use.
• The typical onset of action is within 15-30 minutes.
• They are not intended for use by women or children.
• Patients should inform their physician of all health conditions.
• Do not take more than one dose in 24 hours.
• If adverse reactions occur, seek medical help immediately.
• Avoid excessive physical activity after taking the medication.
• Use in conjunction with healthy lifestyle changes may improve outcomes.
• The tablet should dissolve completely under the tongue.
• Ensure the medication is obtained from reputable sources.

Twenty patients received placebos and the other 20 patients received 20 mg sublingual sildenafil in a double blind randomized design. Results : The effect of sildenafil on erection was significantly higher than that of placebo. Sixty-five percent of patients (13/20) who received sublingual sildenafil achieved satisfying erections and coitus, whereas the rate was 15% in the placebo group (3/20).

How does the sublingual form improve results compared to tablets?The sublingual format allows the tablet to dissolve under the tongue, leading to quicker absorption into the bloodstream. This often means faster action, less waiting time, and a smoother experience compared to traditional swallow tablets.

Minimal headaches, sweating and flushing were noted as the side-effects. Conclusions : 20 mg sublingual sildenafil is safe and effective in the treatment of erectile dysfunction. Sublingual administration has some advantages as it is not effected by food ingestion and quickly appears in the circulation. These advantages provide a faster onset of action with a lower dose when compared to oral sildenafil. Sublingual use of sildenafil may be more cost-effective and possibly provides a more predictable onset of action.

Pulmonary Arterial Hypertension

Twenty mg of sublingual sildenafil shows a significantly higher efficacy than placebo in erectile dysfunction treatment. 65% of patients on sublingual sildenafil achieved satisfactory erections compared to 15% in the placebo group. The average onset of action for sublingual sildenafil was 15.5 minutes, versus 30 minutes for placebo. Sublingual sildenafil administration offers advantages including faster onset and lower required dosage compared to oral forms. The study aims to evaluate the safety and efficacy of sublingual sildenafil versus placebo in erectile dysfunction. The mean onset of action with sublingual sildenafil was 15.5 min and lasted for an average of 40 min. Minimal headaches, sweating and flushing were noted as the side-effects. Conclusions : 20 mg sublingual sildenafil is safe and effective in the treatment of erectile dysfunction. Sublingual administration has some advantages as it is not effected by food ingestion and quickly appears in the circulation. These advantages provide a faster onset of action with a lower dose when compared to oral sildenafil.

Technical Product Specification

We look forward to collaborating with the FDA to file an NDA for ASP-001 for the treatment of ED under the 505(b)2 regulatory pathway and are enthusiastic about the opportunity to make this drug available to patients in the US.” Aspargo Labs announces data on first oral spray for erectile dysfunction, ASP-001, showing two times faster absorption compared to Viagra tablets. Aspargo announces completion of dosing of all subjects in sildenafil oral suspension bioavailability study and initiation of dosing in companion food-effect study. Background : The aim of the present study was to show the efficacy and safety of sublingual sildenafil and to determine whether lower doses cause the same effect with a faster onset of action in this mode of application. Methods : Fourty consecutive patients with erectile dysfunction for more than three months were included in the study. The mean age was 55 years (range, 25-65).

Are you currently using Sildenafil (Viagra, Revatio)?

Serum glucose and testosterone levels, lipid profile and erectile function scores were obtained in all patients. Twenty patients received placebos and the other 20 patients received 20 mg sublingual sildenafil in a double blind randomized design. Results : The effect of sildenafil on erection was significantly higher than that of placebo. Sixty-five percent of patients (13/20) who received sublingual sildenafil achieved satisfying erections and coitus, whereas the rate was 15% in the placebo group (3/20). The mean onset of action with sublingual sildenafil was 15.5 min and lasted for an average of 40 min. Sublingual use of sildenafil may be more cost-effective and possibly provides a more predictable onset of action. Twenty mg of sublingual sildenafil shows a significantly higher efficacy than placebo in erectile dysfunction treatment. 65% of patients on sublingual sildenafil achieved satisfactory erections compared to 15% in the placebo group. The average onset of action for sublingual sildenafil was 15.5 minutes, versus 30 minutes for placebo. Sublingual sildenafil administration offers advantages including faster onset and lower required dosage compared to oral forms.

Why Many Men Choose Sildenafil Citrate 100mg Sublingual

Pulmonary hypertension

The study aims to evaluate the safety and efficacy of sublingual sildenafil versus placebo in erectile dysfunction.